Fel'dblium I V, Vorob'eva N N, Nikolaeva A M, Borisova V N, Mel'nikov V A, Budanov M V, Iakovleva I A, Kaz'ianin A V, Pushkareva E V, Griaznova D V, Shalunova N V, Perelygina O V, Ozeretskovskiĭ N A, Bektimirov T A, Isaeva N V
Medical Academy, Perm, Russia.
Zh Mikrobiol Epidemiol Immunobiol. 2001 Sep-Oct(5):27-30.
Bubo-M, the first Russian associated vaccine, was found to have low reactogenicity and high immunogenic potency. The frequency of postvaccinal reactions in the group of persons immunized with Bubo-M (20%) appeared to be considerably lower than among persons who received the combined injection of adsorbed DT toxoid with reduced antigen content and vaccine against hepatitis B (47.7%). Following the course of vaccination the level of anti-HBs considerably exceeded the protective level. Immune response to the diphtheria and tetanus components of Bubo-M exceeded that observed after immunization with absorbed DT toxoid with reduced antigen content (p < 0.05).